- All Drug Categories
- Home
- Anti-cancer Drugs
- Healthcare Products
- Medical Information
- Statement
The duration of Upadacitinib medication needs to be comprehensively judged based on the type of indication, treatment response, and individual ...
Whether Upadacitinib needs to be taken for a long time depends on the type of indication, treatment response, and individual differences. Most ...
Upadacitinib, as a selective JAK1 inhibitor, has shown significant efficacy in various immune diseases. Its therapeutic effect can be evaluated...
Upadacitinib, as a highly selective JAK1 inhibitor, has shown significant clinical efficacy in the treatment of various autoimmune diseases. It...
Crizotinib, as an ALK/ROS1 inhibitor, has been launched in China. However, attention should be paid to the approval status and medication safet...
Crizotinib has been approved for marketing in China and is mainly used for the treatment of ALK positive non-small cell lung cancer. Patients n...
Crizotinib has significant therapeutic effects on ALK positive non-small cell lung cancer, with an objective remission rate of 60% -80%. It can...
The standard dose of Crizotinib is 250mg orally twice daily and should be taken with meals to increase bioavailability. For special populations...
Eltrombopag is an oral thrombopoietin receptor agonist primarily used to treat thrombocytopenia by stimulating megakaryocyte proliferation and ...
Eltrombopag is an oral thrombopoietin receptor agonist primarily used to treat specific types of thrombocytopenia, including chronic liver di...
